Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.

Abstract

A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 micrograms/ml (0.01, 0.1, and 1.0 micrograms/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 micrograms/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 micrograms/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 +/- 7.4 vs. 34.9 +/- 6.7) and percentage of initial volume (6.4 +/- 4.0 vs. 21.8 +/- 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB-treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

050100'99'01'03'05'07'09'11'13'15'17
Citations per Year

485 Citations

Semantic Scholar estimates that this publication has 485 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Robson1992RecombinantHP, title={Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.}, author={Martin C. Robson and Linda G Phillips and Arien Thomason and Bruce W. Altrock and P C Pence and John P. Heggers and Andrew Johnston and Terrance P McHugh and Mary S. Anthony and Leslie E. Robson}, journal={Annals of plastic surgery}, year={1992}, volume={29 3}, pages={193-201} }